- Home
- NDRA vs QNRX Comparison
NDRA vs QNRX Comparison
Compare NDRA & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDRA | QNRX |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.2M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NDRA | QNRX |
|---|---|---|
| Price | $5.43 | $6.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 11.4K | ★ 835.5K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.96 | $3.25 |
| 52 Week High | $9.83 | $41.80 |
Technical Indicators
Market Signals| Indicator | NDRA | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 75.52 |
| Support Level | $4.72 | $7.00 |
| Resistance Level | $6.08 | $8.97 |
| Average True Range (ATR) | 0.32 | 0.62 |
| MACD | 0.12 | 0.15 |
| Stochastic Oscillator | 86.34 | 88.35 |
Price Performance
Historical ComparisonAbout NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.